EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current Advances in Nanotheranostics for Molecular Imaging and Therapy of Cardiovascular Disorders

Aseem Setia, Abhishesh Kumar Mehata, Vishnu Priya, Datta Maroti Pawde, Dharmendra Jain, Sanjeev Kumar Mahto iD, Madaswamy S Muthu iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00582 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Aseem Setia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh 221005, India. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Theranostic Nanomedicine, Molecular Imaging, Nanoparticles. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 135 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular diseases (CVDs) refer to a collection of conditions characterized by abnormalities in the cardiovascular system. They are a global problem and one of the leading causes of mortality and disability. Nanotheranostics implies to the combination of diagnostic and therapeutic capabilities inside a single nanoscale platform that has allowed for significant advancement in cardiovascular diagnosis and therapy. These advancements are being developed to improve imaging capabilities, introduce personalized therapies, and boost cardiovascular disease patient treatment outcomes. Significant progress has been achieved in the integration of imaging and therapeutic capabilities within nanocarriers. In the case of cardiovascular disease, nanoparticles provide targeted delivery of therapeutics, genetic material, photothermal, and imaging agents. Directing and monitoring the movement of these therapeutic nanoparticles may be done with pinpoint accuracy by using imaging modalities such as cardiovascular magnetic resonance (CMR), computed tomography (CT), positron emission tomography (PET), photoacoustic/ultrasound, and fluorescence imaging. Recently, there has been an increasing demand of noninvasive for multimodal nanotheranostic platforms. In these platforms, various imaging technologies such as optical and magnetic resonance are integrated into a single nanoparticle. This platform helps in acquiring more accurate descriptions of cardiovascular diseases and provides clues for accurate diagnosis. Advances in surface functionalization methods have strengthened the potential application of nanotheranostics in cardiovascular diagnosis and therapy. In this Review, we have covered the potential impact of nanomedicine on CVDs. Additionally, we have discussed the recently developed various nanoparticles for CVDs imaging. Moreover, advancements in the CMR, CT, PET, ultrasound, and photoacoustic imaging for the CVDs have been discussed. We have limited our discussion to nanomaterials based clinical trials for CVDs and their patents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesTheranostic NanomedicineMolecular ImagingNanoparticlesHumansAnimalsMagnetic Resonance ImagingDrug Delivery SystemsPhotoacoustic TechniquesPositron-Emission Tomography

Stichwörter der Autor:innen

Nanotheranosticscardiovascular diseasemolecular imagingnanoparticles

Autor:innen und Institutionen

  • Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh 221005, India.
  • School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be University, Shirpur, Dhule, Maharashtra 425405, India.
  • Department of Cardiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.
  • School of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh 221005, India.

ORCID-Profile: Sanjeev Kumar Mahto, Madaswamy S Muthu

Zitieren

APA

Setia, A., Mehata, A. K., Priya, V., Pawde, D. M., Jain, D., Mahto, S. K., & Muthu, M. S. (2023). Current Advances in Nanotheranostics for Molecular Imaging and Therapy of Cardiovascular Disorders. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00582

Vancouver

Setia A, Mehata AK, Priya V, Pawde DM, Jain D, Mahto SK, et al. Current Advances in Nanotheranostics for Molecular Imaging and Therapy of Cardiovascular Disorders. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00582

BibTeX
@article{Setia2023,
  author = {Setia, Aseem and Mehata, Abhishesh Kumar and Priya, Vishnu and Pawde, Datta Maroti and Jain, Dharmendra and Mahto, Sanjeev Kumar and Muthu, Madaswamy S},
  title = {Current Advances in Nanotheranostics for Molecular Imaging and Therapy of Cardiovascular Disorders},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00582}
}
Kostenlos starten →